Tumors of the hematopoietic and lymphoid tissues

Communities Across the U.S. to Join Olympians at Legendary Deer Valley Resort to End Blood Cancer

Retrieved on: 
Monday, November 6, 2023
ET, Policy, Education, Leukemia, Snow, B-cell leukemia, RYE, Research, Volunteering, Nausea, Dare, Red, LLS, Pedal, Leg, Clinical trial, Packed red blood cells, Leukemia & Lymphoma Society, Bone marrow, One and a Half Summer, Cancer, Acute leukemia, Skiing, Investment, Patient, Back pain, Tumors of the hematopoietic and lymphoid tissues, Nursing care plan, Pharmaceutical industry, Birth control

RYE BROOK, N.Y., Nov. 6, 2023 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is kicking off the ski season with huge goal in mind: to end blood cancer. Communities nationwide will be joined by past Olympians including Nordic skier Bryan Fletcher at LLS's "Shred For Red" event at the legendary Deer Valley Resort in Park City, UT, often referred to as "The Greatest Snow on Earth".

Key Points: 
  • Communities nationwide will be joined by past Olympians including Nordic skier Bryan Fletcher at LLS's " Shred For Red " event at the legendary Deer Valley Resort in Park City, UT, often referred to as "The Greatest Snow on Earth".
  • Happening on December 2, Shred For Red is a fun and family-friendly event where dedicated volunteers raise funds to end blood cancer, while skiing some of the best slopes in the world and enjoying lively winter activities.
  • With a more than 70-year track record, LLS has supported virtually every advancement in blood cancer treatment.
  • Blood cancer patients and their families can contact the LLS Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m., ET.

GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100

Retrieved on: 
Thursday, October 26, 2023
Stem cell, Survival, Bone pain, Gq alpha subunit, Google Store, GPCR, Multiple myeloma, Propranolol, Therapy, Hope, Health, Hematological Cancer Research Investment and Education Act, CXCR4, Sickle cell disease, Research, Cell, ASCT, Mouse, Clinical trial, Risk, Cancer, HSC, G-CSF, G protein-coupled receptor, Transplant, Bone marrow, PLOS, Tumors of the hematopoietic and lymphoid tissues, Biology, Patient, B cell, Seoul National University, Pharmaceutical industry, Microbiology

These findings strongly support the use of this combination for peripheral blood HSC harvest in autologous stem cell transplant treatment in hematological cancers.

Key Points: 
  • These findings strongly support the use of this combination for peripheral blood HSC harvest in autologous stem cell transplant treatment in hematological cancers.
  • The paper, authored in collaboration with Seoul National University’s School of Biological Sciences and Institute of Microbiology, is entitled, “GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol” (1).
  • The authors highlight that GPC-100 alone shows greater mobilization efficacy than a drug already approved for stem cell mobilization.
  • Increasingly, clinicians are using Autologous Stem Cell Transplant (ASCT) to treat patients, which has improved the anti-cancer response and survival compared to conventional chemotherapy.

A.O.U. San Giovanni di Dio Ruggi d'Aragona Expands Usage of SOPHiA GENETICS DDM™ Platform

Retrieved on: 
Thursday, August 17, 2023
Database, Workflow, Tumors of the hematopoietic and lymphoid tissues, NGS, Bone marrow, Inherited disorders of trafficking, Research, Biomarker, Sophia, Sophia Genetics, Data analysis, Patient, Machine learning, GENETICS, Medicine, Artificial intelligence, Diagnosis, Genome, Medical imaging

BOSTON and ROLLE, Switzerland, Aug. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that A.O.U. San Giovanni di Dio Ruggi d'Aragona is now utilizing the SOPHiA DDM™ Platform to advance its research and diagnosis of blood cancers, specifically Myeloma. The hospital, located on the western coast of Italy in Salerno, also leverages SOPHiA GENETICS technology to review rare and inherited disorders.   

Key Points: 
  • San Giovanni di Dio Ruggi d'Aragona is now utilizing the SOPHiA DDM™ Platform to advance its research and diagnosis of blood cancers, specifically Myeloma.
  • San Giovanni di Dio Ruggi d'Aragona Hematology Unit in using NGS testing for the first time.
  • San Giovanni di Dio Ruggi d'Aragona, can still find important biomarkers to research disorders and diagnose their patients.
  • San Giovanni di Dio Ruggi d'Aragona to retain ownership of its database, supporting the research team as it continues to increase its expertise.

Tulane University School of Medicine Uses SOPHiA GENETICS to Advance Research of Blood Cancers

Retrieved on: 
Tuesday, August 8, 2023
Lymphoma, Tulane University School of Medicine, Education, Face, Workflow, Tumors of the hematopoietic and lymphoid tissues, NGS, Bone marrow, Cancer, Research, Biomarker, History, Doctor of Philosophy, Sophia, Malignancy, Sophia Genetics, MD, Data, Blood, GENETICS, Medicine, Artificial intelligence, Multiple myeloma, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, Aug. 8, 2023  /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Tulane University School of Medicine in New Orleans, Louisiana is live on SOPHiA GENETICS technology. The 15th oldest medical school in the United States, Tulane University School of Medicine has a longstanding history of medical research and education and will leverage the SOPHiA DDM™ Platform to help scale its hematologic (blood) testing program to advance blood cancer research.

Key Points: 
  • The 15th oldest medical school in the United States, Tulane University School of Medicine has a longstanding history of medical research and education and will leverage the SOPHiA DDM™ Platform to help scale its hematologic (blood) testing program to advance blood cancer research.
  • said Yuwen Li, MD, PhD, Director of Molecular Genetics Diagnostic Laboratory , Tulane University School of Medicine.
  • The SOPHiA DDM™ Platform will also enable Tulane University School of Medicine to retain custody of its samples and data.
  • "With the adoption of the SOPHiA GENETICS Platform, we are confident that Tulane University School of Medicine will be able to scale its program, further research of blood cancers, and efficiently increase the use of precision medicine."

Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 7, 2023
Myelodysplastic syndrome, AACR, Tumors of the hematopoietic and lymphoid tissues, Salivary gland tumour, Therapy, HER2, DLBCL, Neoplasm, Multiple myeloma, CMC, Control, Cancer, G&A, Research, Burn, SMDC, PDX, Investigational New Drug, Patient, Leukemia, ADC, Spacecraft, R, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Camptothecin, Food, Safety, Pharmaceutical industry, Cryptocurrency

PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • VIP236 is designed to deliver an optimized camptothecin payload to tumors expressing αvβ3, which is found in advanced and metastatic tumors.
  • For the second quarter ended June 30, 2023, Vincerx reported a net loss of approximately $11.2 million, or $0.52 per share.
  • For the second quarter ended June 30, 2022, Vincerx reported a net loss of approximately $18.4 million, or $0.88 per share.
  • For the six-months ended June 30, 2023, Vincerx reported a net loss of $25.5 million, or $1.20 per share, as compared to a net loss of $34.8 million, or $1.66 per share for the same period in 2022.

The Leukemia & Lymphoma Society's 31st Annual Scenic Shore 150 Bike Tour Set to Ride the Shore for a Cure

Retrieved on: 
Tuesday, July 18, 2023
Volunteering, Education, California Coast Classic Bike Tour, RYE, Bone marrow, Clinical trial, Tumors of the hematopoietic and lymphoid tissues, Research, Policy advocacy, LLS, University of Wisconsin–Green Bay, Manitowoc Campus, Leukemia & Lymphoma Society, ET, Patient, Trek, Policy, Scenic, Leukemia, Amusement park, Birth control, Pharmaceutical industry

This wouldn't be possible without the relentless work of thousands of participants and volunteers who raise funds through LLS's impactful events, like the its premier charity cycling event, Scenic Shore 150 Bike Tour.

Key Points: 
  • This wouldn't be possible without the relentless work of thousands of participants and volunteers who raise funds through LLS's impactful events, like the its premier charity cycling event, Scenic Shore 150 Bike Tour.
  • Kicking off this Saturday in Mequon, Wisconsin on July 22, the 31st Annual Scenic Shore 150 Bike Tour is a two-day, 150-mile, fully supported cycling event that is open to riders of all ages and abilities.
  • One of Wisconsin's most popular bike rides, the Scenic Shore 150 is the largest locally organized event for LLS and is a part of the organization's exemplary national campaign portfolio.
  • Through events like Scenic Shore 150 Bike Tour, LLS has invested more than $1.6 billion since its inception in research to advance breakthrough therapies.

ThinkCyte and FIMM Establish Research Partnership to Advance Understanding and Treatment of Blood Cancer

Retrieved on: 
Monday, July 17, 2023
University of Helsinki, Partnership, University, Tumors of the hematopoietic and lymphoid tissues, Bone marrow, Research, Leukemia, Collection, Patient, Artificial intelligence, Diagnosis, Disease

TOKYO, July 17, 2023 /PRNewswire/ -- ThinkCyte today announced a strategic research partnership with the Institute for Molecular Medicine Finland (FIMM-HiLIFE), University of Helsinki aimed at advancing the understanding of leukemia and its treatment.

Key Points: 
  • TOKYO, July 17, 2023 /PRNewswire/ -- ThinkCyte today announced a strategic research partnership with the Institute for Molecular Medicine Finland (FIMM-HiLIFE), University of Helsinki aimed at advancing the understanding of leukemia and its treatment.
  • "Blood cancers are a complex, heterogeneous set of diseases and while the treatment landscape has advanced in recent years, there is still a lot we don't know," said Caroline Heckman, Research Director at FIMM.
  • FIMM hosts the Finnish Hematological Biobank , which is a national biorepository containing an extensive clinical set of leukemia sample series taken at different timepoints of disease and treatment stages (e.g.
  • "We are very excited about the research partnership with FIMM, a global leader in using innovative approaches and technologies to understand and ultimately make a meaningful impact in the lives of patients with blood cancer," said Janette Phi, Chief Business Officer at ThinkCyte.

When Philanthropy and Competition Go Hand-in-Hand: Leaders Nationwide are Helping Blood Cancer Patients Survive and Thrive

Retrieved on: 
Thursday, July 13, 2023
Lymphoma, Myelodysplastic syndrome, Survivor, RYE, Friends, Kammeyer, Leukemia & Lymphoma Society, Workplace, Acute leukemia, Hodgkin lymphoma, Bone marrow, Cancer, Quality of life, Tumors of the hematopoietic and lymphoid tissues, Research, LLS, MDS, Louriza Tronco, Running, All-star, Patient, Man and Woman, Diagnosis, Multiple myeloma, Leukemia, Memory, Social media, Breast cancer, Disease, Pharmaceutical industry, Birth control, Mobile phone

RYE BROOK, N.Y., July 13, 2023 /PRNewswire/ -- Approximately every nine minutes, someone in the U.S. dies from a blood cancer. Through The Leukemia & Lymphoma Society's (LLS) Visionaries of the Year philanthropic competition, thousands of unstoppable go-getters across the U.S. are determined to change this alarming statistic. LLS announced today, Gina Tronco of Albany, NY, was awarded the campaign's prestigious title, "Visionary of the Year," raising over $915,700 for LLS.

Key Points: 
  • RYE BROOK, N.Y., July 13, 2023 /PRNewswire/ -- Approximately every nine minutes, someone in the U.S. dies from a blood cancer.
  • Candidates competed in honor of local blood cancer survivors in their communities.
  • Tronco's family has also been impacted by blood cancer — her cousin, Michael, succumbed to leukemia at just 18-years-old after a five-year battle.
  • Blood cancer patients and their families should contact the LLS Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m.

High School Students Challenge Status Quo in Philanthropic Competition to Support Blood Cancer Patients and Families

Retrieved on: 
Thursday, June 15, 2023
Survivor, Student, RYE, Marketing, SC, Leukemia & Lymphoma Society, Survival, Bone marrow, Clinical trial, Tumors of the hematopoietic and lymphoid tissues, Clover High School, Research, Grandparent, Mentorship, LLS, Acute myeloid leukemia, Entrepreneurship, ET, Patient, Sierra Canyon School, Webb School, Diagnosis, Leukemia, Family, Nursing, Oil, Birth control, Management, Cancer

RYE BROOK, N.Y., June 15, 2023 /PRNewswire/ -- Thousands of relentless high school students across the U.S. are committed to ending blood cancer and helping patients thrive — and through The Leukemia & Lymphoma Society's (LLS) innovative philanthropic competition, Student Visionaries of the Year, they're showing no sign of slowing down.

Key Points: 
  • Formally the iconic "Students of the Year" campaign, Student Visionaries of the Year is a groundbreaking leadership development program for high school students.
  • "LLS is a champion for all blood cancer patients and survivors, and they provide support throughout one's entire cancer experience."
  • Despite the progress, more than a third of blood cancer patients still do not survive five years after their diagnosis.
  • Blood cancer patients and their families can contact the LLS Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m., ET.

Visionaries of the Year: A Campaign Powered by People Imagining a World Without Blood Cancer and Taking Action

Retrieved on: 
Thursday, April 27, 2023
Volunteering, RYE, Bone marrow, Tumors of the hematopoietic and lymphoid tissues, Hope, Coker, LLS, ET, Patient, Diagnosis, Leukemia, Birth control

RYE BROOK, N.Y., April 27, 2023 /PRNewswire/ -- The global leader in the fight against blood cancers, The Leukemia & Lymphoma Society (LLS), officially kicked off its 34th annual Visionaries of the Year — a multimillion-dollar nationwide philanthropic competition. For 10 weeks, thousands of business and community leaders come together with one common goal, end blood cancer.

Key Points: 
  • For 10 weeks, thousands of business and community leaders come together with one common goal, end blood cancer.
  • Everyone involved in Visionaries of the Year (previously Man & Woman of the Year) is committed to "canceling blood cancer".
  • Despite the progress, more than a third of blood cancer patients still do not survive five years after their diagnosis.
  • Blood cancer patients and their families can contact the LLS Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m., ET.